Analyst Ratings For Jazz Pharmaceuticals (NASDAQ:JAZZ)
Today, Jazz Pharmaceuticals (NASDAQ:JAZZ) stock received an upgrade by Morgan Stanley from Equal Weight to Overweight with a price target of $163.75.
Some recent analyst ratings include
- 3/19/2018-Morgan Stanley Upgrade from a “Equal Weight ” rating to a ” Overweight” rating.
- 3/1/2018-Piper Jaffray Companies Reiterated Rating of Buy.
- 1/16/2018-B. Riley Reiterated Rating of Buy.
- 1/2/2018-Leerink Swann initiated coverage with a Outperform rating.
Recent Insider Trading Activity For Jazz Pharmaceuticals (NASDAQ:JAZZ)
Jazz Pharmaceuticals (NASDAQ:JAZZ) has insider ownership of 4.30% and institutional ownership of 91.20%.
- On 3/14/2018 Michael Patrick Miller, EVP, sold 200 with an average share price of $151.12 per share and the total transaction amounting to $30,224.00.
- On 3/9/2018 Bruce C Cozadd, CEO, sold 1,000 with an average share price of $150.00 per share and the total transaction amounting to $150,000.00.
- On 3/6/2018 Matthew P Young, CFO, sold 1,152 with an average share price of $142.36 per share and the total transaction amounting to $163,998.72.
- On 3/6/2018 Paul Treacy, SVP, sold 594 with an average share price of $141.47 per share and the total transaction amounting to $84,033.18.
- On 3/2/2018 Paul Treacy, SVP, sold 877 with an average share price of $139.62 per share and the total transaction amounting to $122,446.74.
- On 2/28/2018 Bruce C Cozadd, CEO, sold 1,000 with an average share price of $150.00 per share and the total transaction amounting to $150,000.00.
- On 2/28/2018 Matthew P Young, CFO, sold 3,135 with an average share price of $146.85 per share and the total transaction amounting to $460,374.75.
Recent Trading Activity for Jazz Pharmaceuticals (NASDAQ:JAZZ)
Shares of Jazz Pharmaceuticals closed the previous trading session at with 186132 shares trading hands.